Field Trip Health Ltd.

Greetings and welcome to Filtrip Fiscal Third Quarter 2022 Earnings Results Conference Call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I'd now like to turn the conference over to your host, Kathleen Heaney of KCSA. Please go ahead.

Thank you. Good morning, everyone, and welcome to Field Trips Fiscal Third Quarter 2022 Financial Results Conference Call. Before we begin the call, I'm obligated to remind everyone that during the course of this conference call, management may be making some forward-looking statements that are based on current expectations and are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations. These results are outlined in the risk factors section of the filing and our disclosure materials. Any forward-looking statements should be considered in light of these factors. Please also note, as safe harbor, any outlook we present is as of today, and management does not undertake any obligations to revise any forward-looking statements in the future. Presenting today will be Joseph Del Moral, co-founder and chief executive officer, Ronan Levy, co-founder and executive chairman, and Donna Wong, chief financial officer. I will now turn the call over to Joseph to provide an update on FieldTrip, in particular, the discovery business.

Thank you, Kathleen, and welcome to everyone joining us this morning. Fieldtrip has continued to build its innovative drug research and development programs, as well as deliver high-quality patient services through its best-in-class clinic network. We are proud of the progress our team has made in developing Fieldtrip into a leading psychedelic-assisted psychotherapy provider and highly recognized brand at the forefront of the psychedelic medicine movement, as we further our mission to deliver innovative treatments for patients in need. We are also particularly pleased to see strong growth in patient revenues in the third fiscal quarter of 2022. The strategic review of our corporate structure that we announced on the last earnings call is still underway. As a reminder, we commenced this review to ensure that each operating unit is best positioned, optimally resourced, and focused to provide maximum long-term value to all stakeholders. We will provide further updates as appropriate. Moving on to field trip discovery, our drug development business. During the quarter, Fieldtrip Discovery progressed on the development of our lead novel psychedelic compound, FT-104. This work is advancing us closer to the development of FT-104 as a more convenient, consistent, and practical psychedelic treatment than is expected to be available through psilocybin and MDMA, should they be approved. FT-104 has the potential to change the lives of those suffering from postpartum depression and treatment-resistant depression. FT-104 is a prodrug of 4-HODIPT. a psychedelic substance identified by Alexander Shulgin as a fast-acting, intense psychedelic, providing a subjective experience similar to psilocybin. FT-104 has improved drug absorption, more reproducible pharmacokinetic profiles, and improved bioavailability relative to 4-HO-DIBT, making it potentially a superior drug candidate. During the quarter, the company expanded consideration for the Phase I trial sites to include Australia, in addition to the Netherlands, to mitigate against possible delays related to regional differences and reactions to the latest COVID surge. As of January, the company finalized agreements with interested parties in Australia to pursue Phase 1 studies and site selection is nearly finalized. The company has received the results of its animal studies, which continue to be reviewed and tabulated. One additional preclinical study remains to be completed and the company expects initiation of Phase 1 to commence on the timelines previously disclosed. We are currently targeting ethics submission before the end of the current calendar quarter. We will keep you apprised of our advancement into phase one. In early January, we received a notice of allowance for our patent application for claims related to FT-104, informally known as isoprosynglutarate. We continue to anticipate that the patent will be issued in Q2. On a separate note, we also progressed our early phase research toward identifying a lead candidate in the FT-200 group, This group has provided potential candidates, which are strong 5-HT2A agonists, with improved selectivity relative to the serotonin 2B antitarget. Reducing off-target serotonin 2B receptor activity reduces the risk of cardiovascular toxicity, and so allowing for potentially safer medications that would have greater flexibility of dosing, such as allowing frequent or chronic dosing, including microdosing administration. We are initiating in vivo behavioral screening tests to determine the activity of these compounds in rodent models of depression. During the quarter, we also filed our first provisional patent application related to the FT-200 group to protect new chemical compositions, potential formulations and uses. This is a very exciting time for Fieldtrip as we continue to lead the way in developing the next generation of psychedelic treatments. I will now hand the call over to Ronan to provide an update on the clinic's business.